Diabetes - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols IGF1R and SOCS2	Name 1 insulin like growth factor 1 receptor	Name2 suppressor of cytokine signaling 2	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 Interleukin-7 signaling Neddylation Negative regulation of FLT3 Growth hormone receptor signaling	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel Novel	Symbols IGF1R and IGF2	Name 1 insulin like growth factor 1 receptor	Name2 insulin like growth factor 2	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 Platelet degranulation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2 Russell-Silver syndrome; Silver-Russell syndrome Beckwith-Wiedemann syndrome Adrenal carcinoma
Novel Novel	Symbols IGF1R and KL	Name 1 insulin like growth factor 1 receptor	Name2 klotho	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel Novel	Symbols IRS1 and TYK2	Name 1 insulin receptor substrate 1	Name2 tyrosine kinase 2	Pathway 1 PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	Pathway 2 Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Other interleukin signaling Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Interleukin-20 family signaling Interleukin-35 Signalling Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Interferon alpha/beta signaling Regulation of IFNA/IFNB signaling Regulation of IFNA/IFNB signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Signaling by ALK fusions and activated point mutants Evasion by RSV of host interferon responses	Drugs 1 [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Drugs 2 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Ruxolitinib Tofacitinib Baricitinib Fostamatinib Abrocitinib Deucravacitinib	Diseases 1	Diseases 2 Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
Novel Novel	Symbols INSR and ENPP1	Name 1 insulin receptor	Name2 ectonucleotide pyrophosphatase/phosphodiesterase 1	Pathway 1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Pathway 2 Vitamin B2 (riboflavin) metabolism Vitamin B5 (pantothenate) metabolism	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2 Taribavirin Polyethylene glycol 400	Diseases 1 Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome	Diseases 2 Ossification of the posterior longitudinal ligament of spine (OPLL) Generalized arterial calcification of infancy Type II diabetes mellitus
Novel Novel	Symbols INSR and SNX4	Name 1 insulin receptor	Name2 sorting nexin 4	Pathway 1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome	Diseases 2
Novel Novel	Symbols INSR and SORBS1	Name 1 insulin receptor	Name2 sorbin and SH3 domain containing 1	Pathway 1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Pathway 2 Smooth Muscle Contraction	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome	Diseases 2
Novel Novel	Symbols JAK2 and IL23R	Name 1 Janus kinase 2	Name2 interleukin 23 receptor	Pathway 1 Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling IFNG signaling activates MAPKs Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	Pathway 2 Interleukin-4 and Interleukin-13 signaling Interleukin-23 signaling Interleukin-23 signaling	Drugs 1 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Pacritinib Baricitinib Entrectinib Fostamatinib Fedratinib Abrocitinib Zanubrutinib Pralsetinib	Drugs 2	Diseases 1 Polycythemia vera	Diseases 2 Crohn's disease
Novel Novel	Symbols BYSL and OSBPL3	Name 1 bystin like	Name2 oxysterol binding protein like 3	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Synthesis of bile acids and bile salts	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BYSL and KATNAL1	Name 1 bystin like	Name2 katanin catalytic subunit A1 like 1	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BYSL and RALY	Name 1 bystin like	Name2 RALY heterogeneous nuclear ribonucleoprotein	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CBL and LTK	Name 1 Cbl proto-oncogene	Name2 leukocyte receptor tyrosine kinase	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Signaling by LTK	Drugs 1	Drugs 2 Fostamatinib	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel Novel	Symbols CBL and LRIG1	Name 1 Cbl proto-oncogene	Name2 leucine rich repeats and immunoglobulin like domains 1	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Signaling by EGFR Negative regulation of MET activity Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel Novel	Symbols CBL and MYH9	Name 1 Cbl proto-oncogene	Name2 myosin heavy chain 9	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Translocation of SLC2A4 (GLUT4) to the plasma membrane Regulation of actin dynamics for phagocytic cup formation EPHA-mediated growth cone collapse Sema4D induced cell migration and growth-cone collapse RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases Activate ROCKs RHO GTPases activate PAKs RHO GTPases activate PAKs Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea CD163 mediating an anti-inflammatory response FCGR3A-mediated phagocytosis Signaling by ALK fusions and activated point mutants	Drugs 1	Drugs 2 Artenimol	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2 MYH9-related kidney diseases, including: Epstein syndrome; Fechtner syndrome Macrothrombocytopenia; May-Hegglin anomaly; Sebastian syndrome; Fechtner syndrome; Epstein syndrome Deafness, autosomal dominant
Novel Novel	Symbols KRT18 and CCDC146	Name 1 keratin 18	Name2 coiled-coil domain containing 146	Pathway 1 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols LMNA and PTPN9	Name 1 lamin A/C	Name2 protein tyrosine phosphatase non-receptor type 9	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Interleukin-37 signaling	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols LMNA and TFRC	Name 1 lamin A/C	Name2 transferrin receptor	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Golgi Associated Vesicle Biogenesis Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle Transferrin endocytosis and recycling RND2 GTPase cycle RND1 GTPase cycle Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin	Drugs 1	Drugs 2 Iron Ferrous sulfate anhydrous Ferric cation Ferrous gluconate Ferrous succinate Ferrous ascorbate Ferrous fumarate Ferrous glycine sulfate Tetraferric tricitrate decahydrate Ferric derisomaltose	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols LMNA and NAT8	Name 1 lamin A/C	Name2 N-acetyltransferase 8 (putative)	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Amyloid fiber formation	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols LMNA and TMEM51	Name 1 lamin A/C	Name2 transmembrane protein 51	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel Novel	Symbols LMNA and SLC13A3	Name 1 lamin A/C	Name2 solute carrier family 13 member 3	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 SLC-mediated transport of organic anions	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols IGF1R and SOCS2	Name 1 insulin like growth factor 1 receptor	Name2 suppressor of cytokine signaling 2	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 Interleukin-7 signaling Neddylation Negative regulation of FLT3 Growth hormone receptor signaling	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel	Symbols IGF1R and IGF2	Name 1 insulin like growth factor 1 receptor	Name2 insulin like growth factor 2	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 Platelet degranulation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2 Russell-Silver syndrome; Silver-Russell syndrome Beckwith-Wiedemann syndrome Adrenal carcinoma
Novel	Symbols IGF1R and KL	Name 1 insulin like growth factor 1 receptor	Name2 klotho	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel	Symbols IRS1 and TYK2	Name 1 insulin receptor substrate 1	Name2 tyrosine kinase 2	Pathway 1 PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	Pathway 2 Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Other interleukin signaling Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Interleukin-20 family signaling Interleukin-35 Signalling Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Interferon alpha/beta signaling Regulation of IFNA/IFNB signaling Regulation of IFNA/IFNB signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Signaling by ALK fusions and activated point mutants Evasion by RSV of host interferon responses	Drugs 1 [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Drugs 2 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Ruxolitinib Tofacitinib Baricitinib Fostamatinib Abrocitinib Deucravacitinib	Diseases 1	Diseases 2 Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
Novel	Symbols INSR and ENPP1	Name 1 insulin receptor	Name2 ectonucleotide pyrophosphatase/phosphodiesterase 1	Pathway 1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Pathway 2 Vitamin B2 (riboflavin) metabolism Vitamin B5 (pantothenate) metabolism	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2 Taribavirin Polyethylene glycol 400	Diseases 1 Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome	Diseases 2 Ossification of the posterior longitudinal ligament of spine (OPLL) Generalized arterial calcification of infancy Type II diabetes mellitus
Novel	Symbols INSR and SNX4	Name 1 insulin receptor	Name2 sorting nexin 4	Pathway 1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome	Diseases 2
Novel	Symbols INSR and SORBS1	Name 1 insulin receptor	Name2 sorbin and SH3 domain containing 1	Pathway 1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Pathway 2 Smooth Muscle Contraction	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome	Diseases 2
Novel	Symbols JAK2 and IL23R	Name 1 Janus kinase 2	Name2 interleukin 23 receptor	Pathway 1 Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling IFNG signaling activates MAPKs Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	Pathway 2 Interleukin-4 and Interleukin-13 signaling Interleukin-23 signaling Interleukin-23 signaling	Drugs 1 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Pacritinib Baricitinib Entrectinib Fostamatinib Fedratinib Abrocitinib Zanubrutinib Pralsetinib	Drugs 2	Diseases 1 Polycythemia vera	Diseases 2 Crohn's disease
Novel	Symbols BYSL and OSBPL3	Name 1 bystin like	Name2 oxysterol binding protein like 3	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Synthesis of bile acids and bile salts	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BYSL and KATNAL1	Name 1 bystin like	Name2 katanin catalytic subunit A1 like 1	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BYSL and RALY	Name 1 bystin like	Name2 RALY heterogeneous nuclear ribonucleoprotein	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CBL and LTK	Name 1 Cbl proto-oncogene	Name2 leukocyte receptor tyrosine kinase	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Signaling by LTK	Drugs 1	Drugs 2 Fostamatinib	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel	Symbols CBL and LRIG1	Name 1 Cbl proto-oncogene	Name2 leucine rich repeats and immunoglobulin like domains 1	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Signaling by EGFR Negative regulation of MET activity Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel	Symbols CBL and MYH9	Name 1 Cbl proto-oncogene	Name2 myosin heavy chain 9	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Translocation of SLC2A4 (GLUT4) to the plasma membrane Regulation of actin dynamics for phagocytic cup formation EPHA-mediated growth cone collapse Sema4D induced cell migration and growth-cone collapse RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases Activate ROCKs RHO GTPases activate PAKs RHO GTPases activate PAKs Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea CD163 mediating an anti-inflammatory response FCGR3A-mediated phagocytosis Signaling by ALK fusions and activated point mutants	Drugs 1	Drugs 2 Artenimol	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2 MYH9-related kidney diseases, including: Epstein syndrome; Fechtner syndrome Macrothrombocytopenia; May-Hegglin anomaly; Sebastian syndrome; Fechtner syndrome; Epstein syndrome Deafness, autosomal dominant
Novel	Symbols KRT18 and CCDC146	Name 1 keratin 18	Name2 coiled-coil domain containing 146	Pathway 1 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols LMNA and PTPN9	Name 1 lamin A/C	Name2 protein tyrosine phosphatase non-receptor type 9	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Interleukin-37 signaling	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols LMNA and TFRC	Name 1 lamin A/C	Name2 transferrin receptor	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Golgi Associated Vesicle Biogenesis Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle Transferrin endocytosis and recycling RND2 GTPase cycle RND1 GTPase cycle Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin	Drugs 1	Drugs 2 Iron Ferrous sulfate anhydrous Ferric cation Ferrous gluconate Ferrous succinate Ferrous ascorbate Ferrous fumarate Ferrous glycine sulfate Tetraferric tricitrate decahydrate Ferric derisomaltose	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols LMNA and NAT8	Name 1 lamin A/C	Name2 N-acetyltransferase 8 (putative)	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 Amyloid fiber formation	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols LMNA and TMEM51	Name 1 lamin A/C	Name2 transmembrane protein 51	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2
Novel	Symbols LMNA and SLC13A3	Name 1 lamin A/C	Name2 solute carrier family 13 member 3	Pathway 1 XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions	Pathway 2 SLC-mediated transport of organic anions	Drugs 1	Drugs 2	Diseases 1 Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy	Diseases 2

Page 25 out of 58 pages

Search Results : Diabetes